Home » News » Drug Sponsors » Bayer to divest interventional device business to Boston Scientific

Bayer to divest interventional device business to Boston Scientific

Friday, May 16, 2014

Bayer HealthCare will sell its interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is $415 million.

The sale will include the AngioJet (thrombectomy) and Jetstream (atherectomy) systems, and the Fetch2 Aspiration Catheter used in cardiology, radiology and peripheral vascular procedures. Closing is expected in the second half of 2014.

“With this sale, our medical care division can concentrate on innovation and growth in radiology and diabetes care, where we already have a strong presence,” said Dr. Olivier Brandicourt, CEO of Bayer HealthCare.

“The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions,” said Jeff Mirviss, president, Peripheral Interventions, Boston Scientific.

Bayer’s Interventional business accounted for approximately $120 million in sales in 2013.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!